Treatment of preterm labor

Journal of Perinatal and Neonatal Nursing

Volumn 16, Issue 1, 2002, Pages 25-46

  Witcher, Patricia Sauer ^a  

^a NORTHSIDE HOSPITAL   (United States)

Author keywords

Preterm labor treatment; Tocolysis; Tocolytic therapy

Indexed keywords

UTERUS SPASMOLYTIC AGENT;

BED REST; FEMALE; FLUID THERAPY; HUMAN; METHODOLOGY; MULTIMODALITY CANCER THERAPY; NEWBORN NURSING; NURSING ASSESSMENT; PREGNANCY; PREMATURE LABOR; REVIEW; TIME; TOCOLYSIS; TREATMENT OUTCOME;

BED REST; COMBINED MODALITY THERAPY; FEMALE; FLUID THERAPY; HUMANS; NEONATAL NURSING; NURSING ASSESSMENT; OBSTETRIC LABOR, PREMATURE; PREGNANCY; TIME FACTORS; TOCOLYSIS; TOCOLYTIC AGENTS; TREATMENT OUTCOME;

EID: 0036597333     PISSN: 08932190     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005237-200206000-00005     Document Type: Article

References (75)

1. American College of Obstetricians and Gynecologists (ACOG). Assessment of Risk Factors for Preterm Birth. Washington, DC: ACOG; 2001. ACOG Practice Bulletin 31.
2. Synnes AR, Ling EWY, Whitfield MF, et al. Perinatal outcomes of a large cohort of extremely low gestational age infants (twenty-three to twenty-eight completed weeks of gestation). J Pediatr. 1994;125(6, pt 1):952-960.
3. Lefbvre F, Glorieux J, St-Laurent-Gagnon T. Neonatal survival and disability rate at age 18 months for infants born between 23 and 28 weeks of gestation. Am J Obstet Gynecol. 1996;174(3):833-838.
4. Robertson PA, Sniderman SH, Laros RK Jr, et al. Neonatal morbidity according to gestational age and birth weight from five tertiary care centers in the United States, 1983 through 1986. Am J Obstet Gynecol. 1992;166(6, pt 1):1629-1645.
5. Amon E, Midkiff C, Winn H, et al. Tocolysis with advanced cervical dilatation. Obstet Gynecol. 2000;95(3):358-362.
6. Creasy RK, lams JD. Preterm labor and delivery. In: Creasy RK, Resnik R, eds. Maternal-Fetal Medicine. 4th ed. Philadelphia: W.B. Saunders; 1999.
7. Steer P, Flint C. ABC of labour care. Preterm labour and premature rupture of membranes. Br Med J. 1999;318(7190): 1059-1062.
8. Lopez RL, Francis JA, Garite TJ, Dubyak JM. Fetal fibronectin detection as a predictor of preterm birth in actual clinical practice. Am J Obstet Gynecol. 2000;182(5):1103-1106.
9. Peaceman AM, Andrews WW, Thorp JM, et al. Fetal fibronectin as a predictor of preterm birth in patients with symptoms: a multicenter trial. Am J Obstet Gynecol. 1997;177(1):13-18.
10. Joffe GM, Jacques D, Bemis-Heys R, et al. Impact of the fetal fibronectin assay on admissions for preterm labor. Am J Obstet Gynecol. 1999;180(3, pt 1):581-586.
11. Nageotte MP, Casal D, Senyei AE. Fetal fibronectin in patients at increased risk for premature birth. Am J Obstet Gynecol. 1994;170(1, pt 1):20-25.
12. Goldenberg RL, Hauth JC, Andrews WW. Intrauterine infection and preterm delivery. N Engl J Med. 2000;342(20):1500-1507.
13. Maloni JA, Breninski-Tonmasi JE, Johnson LA. Antepartum bed rest: effect upon the family. J Obstet Gynecol Neonatal Nurs. 2001;30(2):165-173.
14. MacLennan AH, Green RC, O'Shea R, Brookes C, Morris D. Routine hospital admission in twin pregnancy between 26 and 30 weeks' gestation. Lancet. 1990;335:267-269.
15. Saunders MC, Dick JS, Brown IM, McPherson K, Chalmers I. The effects of hospital admission for bed rest on the duration of twin pregnancy: a randomised trial. Lancet. 1985;2(8459):793-795.
16. Kovacevich GJ, Gaich SA, Lavin JP, et al. The prevalence of thromboembolic events among women with extended bedrest prescribed as part of the treatment for premature labor or preterm premature rupture of membranes. Am J Obstet Gynecol. 2000;182(5):1089-1092.
17. Danilenko-Dixon DR, Heit JA, Silverstein MC, et al. Risk factors for deep vein thrombosis and pulmonary embolism during pregnancy or postpartum: a population-based, case-control study. Am J Obstet Gynecol. 2001;184(2):104-110.
18. Laros RK. Thromboembolic disease. In: Gabbe SG, Niebyl JR, Simpson JL, eds. Obstetrics: Normal and Problem Pregnancies. 3rd ed. New York: Churchill Livingstone; 1996.
19. Hearne AE, Nagey DA. Therapeutic agents in preterm labor: tocolytic agents. Clin Obstet Gynecol. 2000;43(4):787-801.
20. Flynn K. Preterm labor and premature rupture of membranes. In: Mandeville LK, Troiano NH, eds. High Risk and Critical Care Intrapartum Nursing. 2nd ed. Philadelphia: J.B. Lippincott; 1999.
21. Parilla BV, Dooley SL, Minogue JP, Socol ML. The efficacy of oral terbutaline after intravenous tocolysis. Am J Obstet Gynecol. 1993;169(4):965-969.
22. Sanchez-Ramos L, Kaunitz AM, Gaudier FL, Delke I. Efficacy of maintenance therapy after acute tocolysis: a meta-analysis. Am J Obstet Gynecol. 1999;181(2):484-490.
23. Hill WH. Risks and complications of tocolysis. Clin Obstet Gynecol. 1995; 38(4):725-745.
24. Guinn DA, Goldenberg RL, Cliver SP, Owen J. Relationship of gestational age and cervical dilation to the timing of delivery. Int J Gynecol Obstet. 1999;64:233-237.
25. De Veciana M, Porto M, Major CA, Barke JI. Tocolysis in advanced preterm labor: impact on neonatal outcome. Am J Perinatol. 1995;12(4):294-298.
26. Garite TJ. Premature rupture of membranes. In: Gabbe SG, Niebyl JR, Simpson JL, eds. Obstetrics: Normal and Problem Pregnancies. 3rd ed. New York: Churchill Livingstone; 1996.
27. Harlass FE. The use of tocolytics in patients with preterm premature rupture of membranes. Clin Obstet Gynecol. 1991;34(4):751-758.
28. Allbert JR, Naef RW, Perry KG, et al. Amniotic fluid interleukin-6 and interleukin-8 levels predict the success of tocolysis in patients with preterm labor. J Soc Gynecol Invest. 1994;1(4):264-268.
29. Sciscione AC, Stamilio DM, Manley JS, et al. Tocolysis of preterm contractions does not improve preterm delivery rate or perinatal outcomes. Am J Perinatol. 1998;15(3):177-181.
30. Iams JD. Preterm birth. In: Gabbe SG, Niebyl JR, Simpson JL, eds. Obstetrics: Normal and Problem Pregnancies. 3rd ed. New York: Churchill Livingstone; 1996.
31. Creasy RK. Preterm birth prevention: where are we? Am J Obstet Gynecol. 1993; 168(4):1223-1230.
32. Higby K, Xenakis EMJ, Pauerstein CJ. Do tocolytics stop preterm labor? A critical and comprehensive review of efficacy and safety. Am J Obstet Gynecol. 1993;168(4):1247-1259.
33. Fox MD, Allbert JR, McCaul JF, et al. Neonatal morbidity between 34 and 37 weeks' gestation. J Perinatol. 1993;13(5):349-353.
34. Bernai AL, Tambyraja RL. Preterm labour. Baillieres Clin Obstet Gynecol. 2000;14(1):133-153.
35. Smigaj D, Roman-Drago NM, Amini SB, et al. The effect of oral terbutaline on maternal glucose metabolism and energy expenditure in pregnancy. Am J Obstet Gynecol. 1998;178(5):1041-1047.
36. Bader AM, Boudier E, Martinez C, et al. Etiology and prevention of pulmonary complications following beta-mimetic mediated tocolysis. Eur J Obstet Gynecol. 1998;80:133-137.
37. Braden GL, Von Oeyen PT, Germain J, Watson DJ, Haag BL. Ritodrine-and terbutaline-induced hypokalemia in preterm labor: mechanisms and consequences. Int Soc Nephrol. 1997:51:1867-1875.
38. Norwitz ER, Robinson JN, Challis JRG. The control of labor. N Engl J Med. 1999;341(9):660-666.
39. Perry KG, Morrison JC, Rust OA, et al. Incidence of adverse cardiopulmonary effects with low-dose continuous terbutaline infusion. Am J Obstet Gynecol. 1995;173(4):1273-1277.
40. Sala DJ, Moise KJ. The treatment of preterm labor using a portable subcutaneous terbutaline pump. J Obstet Gynecol Neonatal Nurs. 1990;19(2):108-115.
41. Guinn DA, Boepfert AR, Owen J, Wenstrom KD, Hauth JC. Terbutaline pump maintenance therapy for prevention of preterm delivery: a double-blind trial. Am J Obstet Gynecol. 1998;179(4):874-878.
42. Cox SM, Sherman L, Leveno KJ. Randomized investigation of magnesium sulfate for prevention of preterm birth. Am J Obstet Gynecol. 1990;163(3):767-772.
43. Ricci JM, Hariharan S, Helfgott A, Reed K, O'Sullivan MJ. Oral tocolysis with magnesium chloride: a randomized controlled prospective clinical trial. Am J Obstet Gynecol. 1991;165(3):603-610.
44. Lewis DF, Bergstedt S, Edwards MS, et al. Successful magnesium sulfate tocolysis: is "weaning" the drug necessary? Am J Obstet Gynecol. 1997;177(4):742-745.
45. Terrone DA, Rinehart BK, Kimmel ES, et al. A prospective, randomized, controlled trial of high and low maintenance doses of magnesium sulfate for acute tocolysis. Am J Obstet Gynecol. 2000;182(6):1477-1482.
46. Yeast JD, Halberstadt C, Meyer BA, Cohen GR, Thorp JA. The risk of pulmonary edema and colloid asmotic pressure changes during magnesium sulfate infusion. Am J Obstet Gynecol. 1993;169(6): 1566-1571.
47. Kosasa T, Busse R, Wahl N, et al. Long-term tocolysis with combined intravenous terbutaline and magnesium sulfate: a 10-year study of 1,000 patients. Obstet Gynecol. 1994;84(3):369-373.
48. Holcomb WL, Shackelford GD, Petrie RH. Magnesium tocolysis and neonatal bone abnormalities: a controlled study. Obstet Gynecol. 1991;78(4):611-614.
49. Myers DA, Nathanielsz PW. Biologic basis of term and preterm labor. Clin Perinatol. 1993;20(1):9-28.
50. Papatsonis DNM, Van Geijn HP, Ader HJ, et al. Nifedipine and ritodrine in the management of preterm labor: a randomized multicenter trial. Obstet Gynecol. 1997;90(2):230-234.
51. Macones GA, Marder SJ, Clotheir B, Stamilio DM. The controversy surrounding indomethacin for tocolysis. Am J Obstet Gynecol. 2001;184(3):264-272.
52. Lunt CC, Satin AJ, Barth WH, Hankins GDV. The effect of indomethacin tocolysis on maternal coagulation status. Obstet Gynecol. 1994;84(5):820-822.
53. Bivins HA, Newman R, Fyfe DA, Campbell BA, Stramm SL. Randomized trial of oral indomethacin and terbutaline sulfate for the long-term suppression of preterm labor. Am J Obstet Gynecol. 1993;169(4):1065-1070.
54. Besinger RE, Niebyl A, Keyes WG, Johnson RBJ. Randomized comparative trial of indomethacin and ritodrine for the long-term treatment of preterm labor. Am J Obstet Gynecol. 1991;164(4):981-988.
55. Rasanen J, Jouppila P. Fetal cardiac function and ductus arteriosus during indomethacin and sulindac therapy for threatened preterm labor: a randomized study. Am J Obstet Gynecol. 1995;173(1): 20-25.
56. Vermillion ST, Scardo JA, Lashus AG, Wiles HB. The effect of indomethacin tocolysis on fetal ductus arteriosus constriction with advancing gestational age. Am J Obstet Gynecol. 1997;177(2):256-261.
57. Vermillion S, Newman R. Neonatal complications associated with indomethacin tocolysis in very preterm infants. Am J Obstet Gynecol. 1999;80(1, pt 2):351.
58. Iannucci TA, Bensinger RE, Fisher SG, Gianopoulos JG, Tomich PG. Effect of dual tocolysis on the incidence of severe intraventricular heomorrhage among extremely low birth weight infants. Am J Obstet Gynecol. 1996;175(4, pt 1):1043-1046.
59. Kirschbaum T. Antibiotics in the treatment of preterm labor. Am J Obstet Gynecol. 1993;168(4):1239-1246.
60. Reimer T, Ulfig N, Friese K. Antibiotics: treatment of preterm labor. J Perinatol Med. 1999;27:35-40.
61. Stetzer BP, Mercer BM. Antibiotics and preterm labor. Clin Obstet Gynecol. 2000;43(4):809-817.
62. American College of Obstetricians and Gynecologists (ACOG). Antenatal Corticosteroid Therapy for Fetal Maturation. ACOG Committee Opinion. Washington, DC: ACOG; 1998.
63. Banks DA, Cnaan A, Morgan MA, et al. Multiple courses of antenatal corticosteroids and outcome of premature neonates. Am J Obstet Gynecol. 1999; 181(3):709-717.
64. McNamara MF, Bottoms SF. The incidence of respiratory distress syndrome does not increase when preterm delivery occurs greater than 7 days after steroid administration. Aust N Z J Obstet Gynaecol. 1998;38:8-10.
65. Guinn DA, BMZ Study Group. Multicenter randomized trial of single versus weekly courses of antenatal corticosteroids (ACS): interim analysis. Am J Obstet Gynecol. 2000;182(1):S12.
66. Pratt L, Waschbusch L, Ladd W, et al. Multiple vs single betamethasone therapy: neonatal and maternal effects. J Reprod Med. 1999;44(3):254-264.
67. National Institutes of Health. Antenatal corticosteroids revisited: repeat courses. NIH Consens Statement. 2000:17(2):1-18.
68. Esters DM, Pass J, Egan JFX. Serial betamethasone use in clinic practice: does it affect fetal growth? Am J Obstet Gynecol. 2000;182(1):S57.
69. French JI, McGregor JA, Draper D, Parker R, McFee J. Gestational bleeding, bacterial vaginosis, and common reproductive tract infections: risk for preterm birth and benefit of treatment. Obstet Gynecol. 1999;93(5, pt 1):715-724.
70. Huang WL, Beazley LD, Quinlivan JA, et al. Effect of corticosteroids on brain growth in fetal sheep. Obstet Gynecol. 1999;94(2):213-218.
71. Jobe AH, Newnham J, Willet K, et al. Fetal versus maternal and gestational age effects of repetitive antenatal glucocorticoids. Pediatrics. 1998;102(5):1116-1125.
72. Jobe AH, Wada N, Berry LM, et al. Single and repetitive maternal glucocorticoid exposures reduce fetal growth in sheep. Am J Obstet Gynecol. 1998;178(5):880-885.
73. Quinlivan JA, Archer MA, Dunlop SA, et al. Fetal growth retardation, particularly within lymphoid organs, following repeated maternal injections of betamethasone in sheep. J Obstet Gynecol Res. 1998;24(3):173-182.
74. Sinervo K, Lange I. Maternal and neonatal outcomes following single versus multiple courses of corticosteroids. Am J Obstet Gynecol. 2000;182(1):S52.
75. Fausett SM, Smith S, Oshiro BT, et al. Multiple courses of antenatal steroids are associated with a delay in long-term psychomotor development in children with birth weights <1,500 grams. Am J Obstet Gynecol. 2000;182(1):S24.